Noboru Hirashima

Overview

Explore the profile of Noboru Hirashima including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 39

Citations 469

Followers 0

Related Specialties

Gastroenterology

Oncology

General Medicine

Top 10 Co-Authors

Yasuhito Tanaka

Masaaki Shimada

Masashi Mizokami

Etsuro Orito

Izumi Hasegawa

Ryuzo Ueda

Kenji Sakakibara

Hiroaki Iwase

Tomoyoshi Ohno

Fuminaka Sugauchi

Published In

Hepatol Res

J Gastroenterol

Gan To Kagaku Ryoho

Clin J Gastroenterol

Liver Int

Affiliations

Soon will be listed here.

Recent Articles

11.

TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy

Iio E, Matsuura K, Shimada N, Atsukawa M, Itokawa N, Abe H, et al.

J Gastroenterol . 2018 Nov; 54(4):339-346. PMID: 30382363

Background: The aim of this study is to ascertain whether the TLL1 variant at rs17047200 is associated with the development of HCC after achieving sustained virological response (SVR) by interferon...

12.

Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population

Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, et al.

Hum Mol Genet . 2017 Jan; 26(3):650-659. PMID: 28062665

A previous genome-wide association study (GWAS) performed in 963 Japanese individuals (487 primary biliary cholangitis [PBC] cases and 476 healthy controls) identified TNFSF15 (rs4979462) and POU2AF1 (rs4938534) as strong susceptibility...

13.

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir

Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, et al.

Clin J Gastroenterol . 2016 Oct; 10(1):41-46. PMID: 27766544

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) often accelerates the course of HCV-associated liver disease. Daclatasvir (DCV) plus asunaprevir (ASV) have been shown to be highly...

14.

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, et al.

J Gastroenterol . 2016 May; 52(1):94-103. PMID: 27236547

Background: The present study explored the treatment outcome of daclatasvir (DCV) and asunaprevir (ASV) therapy combining oral direct-acting antiviral agents (DAAs) for chronic hepatitis C (HCV) including liver cirrhosis according...

15.

An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin

Hirashima N, Iwase H, Shimada M, Imamura J, Sugiura W, Yokomaku Y, et al.

Intern Med . 2015 Sep; 54(17):2173-7. PMID: 26328642

We herein describe the case of a 42-year-old man who developed severe hepatitis caused by hepatitis C virus (HCV) infection at 14 years after the start of human immunodeficiency virus...

16.

Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population

Migita K, Nakamura M, Abiru S, Jiuchi Y, Nagaoka S, Komori A, et al.

PLoS One . 2013 Aug; 8(8):e71382. PMID: 23990947

Background/aims: Recent studies demonstrated an association of STAT4 polymorphisms with autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, indicating multiple autoimmune diseases share common susceptibility genes. We therefore investigated...

17.

Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial

Iwase H, Shimada M, Tsuzuki T, Hirashima N, Okeya M, Hibino Y, et al.

Oncology . 2013 May; 84(6):342-9. PMID: 23689040

Objectives: A phase II study was performed to investigate the safety and efficacy of concurrent chemoradiotherapy (CCRT) combined with an orally active fluoropyrimidine, S-1, plus cisplatin for locally advanced esophageal...

18.

Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population

Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, et al.

Am J Hum Genet . 2012 Sep; 91(4):721-8. PMID: 23000144

For the identification of susceptibility loci for primary biliary cirrhosis (PBC), a genome-wide association study (GWAS) was performed in 963 Japanese individuals (487 PBC cases and 476 healthy controls) and...

19.

[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center]

Tsuzuki T, Iwase H, Shimada M, Hirashima N, Hibino Y, Ryuge N, et al.

Nihon Shokakibyo Gakkai Zasshi . 2012 Jul; 109(7):1186-96. PMID: 22790623

At Nagoya Medical Center, 10 patients co-infected with HIV and HCV received peginterferon α (PEG-IFNα) plus ribavirin therapy. Three of the cases were HCV genotype 1b, 2 cases were HCV...

20.

Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C

Kaneko S, Sata M, Ide T, Yamashita T, Hige S, Tomita E, et al.

Hepatol Res . 2010 Oct; 40(11):1072-81. PMID: 20880058

Aim: Efficacy and safety of double filtration plasmapheresis (DFPP) for chronic hepatitis C were prospectively analyzed in Japanese clinical settings. Methods: All patients who received DFPP in combination with interferon...